FR2518993B1 - 2-(4-((4,4-dialkyl-2,6-piperidinedion-1-yl))-1-piperazinyl) pyrimidines, leur preparation et leur application pharmacologique - Google Patents

2-(4-((4,4-dialkyl-2,6-piperidinedion-1-yl))-1-piperazinyl) pyrimidines, leur preparation et leur application pharmacologique

Info

Publication number
FR2518993B1
FR2518993B1 FR8221750A FR8221750A FR2518993B1 FR 2518993 B1 FR2518993 B1 FR 2518993B1 FR 8221750 A FR8221750 A FR 8221750A FR 8221750 A FR8221750 A FR 8221750A FR 2518993 B1 FR2518993 B1 FR 2518993B1
Authority
FR
France
Prior art keywords
piperidinedion
pyrimidines
piperazinyl
dialkyl
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8221750A
Other languages
English (en)
Other versions
FR2518993A1 (fr
Inventor
Davis L Temple
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of FR2518993A1 publication Critical patent/FR2518993A1/fr
Application granted granted Critical
Publication of FR2518993B1 publication Critical patent/FR2518993B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
FR8221750A 1981-12-28 1982-12-24 2-(4-((4,4-dialkyl-2,6-piperidinedion-1-yl))-1-piperazinyl) pyrimidines, leur preparation et leur application pharmacologique Expired FR2518993B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/334,688 US4423049A (en) 1981-12-28 1981-12-28 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines

Publications (2)

Publication Number Publication Date
FR2518993A1 FR2518993A1 (fr) 1983-07-01
FR2518993B1 true FR2518993B1 (fr) 1986-09-05

Family

ID=23308351

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8221750A Expired FR2518993B1 (fr) 1981-12-28 1982-12-24 2-(4-((4,4-dialkyl-2,6-piperidinedion-1-yl))-1-piperazinyl) pyrimidines, leur preparation et leur application pharmacologique

Country Status (26)

Country Link
US (1) US4423049A (fr)
JP (2) JPS58118582A (fr)
KR (1) KR870001045B1 (fr)
AT (1) AT382373B (fr)
AU (1) AU555797B2 (fr)
BE (1) BE895504A (fr)
CA (1) CA1244426A (fr)
CH (1) CH656383A5 (fr)
CY (1) CY1379A (fr)
DE (1) DE3248160C2 (fr)
DK (1) DK162389C (fr)
ES (2) ES518510A0 (fr)
FI (1) FI70891C (fr)
FR (1) FR2518993B1 (fr)
GB (1) GB2114122B (fr)
GR (1) GR77045B (fr)
HK (1) HK5288A (fr)
IE (1) IE54619B1 (fr)
IT (1) IT1158039B (fr)
KE (1) KE3709A (fr)
LU (1) LU84561A1 (fr)
NL (1) NL193283C (fr)
PT (1) PT76036B (fr)
SE (1) SE453088B (fr)
SG (1) SG29787G (fr)
ZA (1) ZA828549B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4581357A (en) * 1983-02-07 1986-04-08 Mead Johnson & Company Antipsychotic 5-fluoro-pyrimidin-2-yl piperazine compound
US5187276A (en) * 1983-06-18 1993-02-16 Troponwerke Gmbh & Co. Kg. 2-pyrimidinyl-1-piperazine derivatives
DE3321969A1 (de) * 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
CA1250291A (fr) * 1984-07-23 1989-02-21 Bristol-Myers Company Derives 1-(2-pyrimidinyl)-piperazinyliques de l-pyrrolidin-2-ones, agents psychogeriatriques
HUT43600A (en) * 1985-06-22 1987-11-30 Sandoz Ag Process for production of new thiazole derivatives and medical compound containing those
NZ216720A (en) * 1985-07-08 1990-09-26 Bristol Myers Co Diazinylpiperidine derivatives and pharmaceutical compositions
US4826843A (en) * 1985-07-08 1989-05-02 Bristol-Myers Cerebral function enhancing diazinylpiperidine derivatives
US4777254A (en) * 1986-12-02 1988-10-11 American Home Products Corp. Cyclic imides as H1 -antagonists
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US4782060A (en) * 1987-07-29 1988-11-01 Bristol-Myers Company Gepirone for alleviation of panic disorders
US4880930A (en) * 1987-11-30 1989-11-14 New James S Psychotropic acyclic amide derivatives
US5116970A (en) * 1988-02-18 1992-05-26 New James S Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones
US5001130A (en) * 1988-02-18 1991-03-19 Bristol-Myers Company Psychotropic heterobicycloalkylpiperazine derivatives
US4780466A (en) * 1988-03-17 1988-10-25 Hoechst-Roussel Pharmaceuticals, Inc. Arylpiperazinylalkoxy derivatives of cyclic imides
US5242911A (en) * 1988-06-17 1993-09-07 Pfizer Inc. Bridged bicyclic imides as anxiolytics and antidepressants
US5077295A (en) * 1988-09-16 1991-12-31 Pfizer Inc. Antipsychoic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)buytl bridged bicycle imides
FR2654934B1 (fr) * 1989-11-29 1994-09-30 Midy Spa Utilisation de derive [4-(2-pyrimidinyl)-1-piperazinyl] butyliques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale.
US5098904A (en) * 1990-06-27 1992-03-24 Bristol-Myers Squibb Company Cerebral function enhancing pyrimidinyl derivatives
AU9164591A (en) * 1990-12-14 1992-07-08 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DE4135551A1 (de) * 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
GB9223153D0 (en) * 1992-11-05 1992-12-16 Wyeth John & Brother Ltd Piperazine derivatives
FR2701260B1 (fr) * 1993-02-05 1995-05-05 Esteve Labor Dr Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
US5338738A (en) * 1993-04-19 1994-08-16 Bristol-Myers Squibb Company Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
FR2705098B1 (fr) * 1993-05-10 1995-08-04 Esteve Labor Dr Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) .
US5538985A (en) * 1994-01-27 1996-07-23 Mitsui Toatsu Chemicals, Inc. Pyrrolidinone derivatives
US5521313A (en) * 1994-05-05 1996-05-28 Bristol-Myers Squibb Company Process for preparing certain azapirones
CA2146593A1 (fr) * 1994-05-05 1995-11-06 Jack Melton Procede pour la synthese a grande echelle d'azapirone
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
WO2000006163A1 (fr) * 1998-07-30 2000-02-10 Bristol-Myers Squibb Company Methode amelioree de traitement de troubles respiratoires lies au sommeil
US6566361B2 (en) 1999-06-30 2003-05-20 Laboratories, Upsa Azapirone pain treatment
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
CN100367965C (zh) * 1999-12-20 2008-02-13 法布瑞－克雷默制药有限公司 吉吡隆代谢物在制备改善哺乳动物不良心理状态的组合物上的应用
KR20020068404A (ko) * 2000-01-19 2002-08-27 악조 노벨 엔.브이. 미르타자핀을 포함하는, 우울증 및 관련 장애 치료용 약물조합물
AU2001295478A1 (en) * 2000-08-22 2002-03-04 Akzo Nobel N.V. Active metabolite of gepirone
WO2002044159A2 (fr) * 2000-11-29 2002-06-06 Eli Lilly And Company 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine, ses sels acceptables sur le plan pharmaceutique et ses solvants
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
JP4838128B2 (ja) * 2003-07-30 2011-12-14 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピペラジン誘導体および治療剤としてのその用途
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
US20060099267A1 (en) * 2004-11-05 2006-05-11 Fabre-Kramer Pharmaceuticals, Inc. High-dosage extended-release formulation of gepirone
WO2006052227A1 (fr) * 2004-11-05 2006-05-18 Fabre-Kramer Holdings, Inc. Preparation de gepirone a liberation prolongee hautement dosee
PT2159226T (pt) * 2007-03-29 2016-12-16 Joint-Stock Company Obninsk Chemical Pharmaceutical Company Agente anti-histamínico e antialérgico e um método para a produção do mesmo
WO2011030139A1 (fr) * 2009-09-11 2011-03-17 Astrazeneca Ab Derives de 4-(pyrimidin-2-yl)-piperazine et de 4-(pyrimidin-2-yl)-piperidine utilises en tant que modulateurs du gpr119
IT201900000657A1 (it) 2019-01-16 2020-07-16 Procos Spa Processo per la sintesi di gepirone
GB202014736D0 (en) * 2020-09-18 2020-11-04 Imperial College Innovations Ltd Novel compounds and their use in therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3398151A (en) * 1966-02-01 1968-08-20 Mead Johnson & Co Azaspirodecanediones and azaspiroundecanediones
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
FI791926A (fi) 1978-06-20 1979-12-21 Synthelabo Fenylpiperazinderivat
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines

Also Published As

Publication number Publication date
HK5288A (en) 1988-01-29
FI824442A0 (fi) 1982-12-23
IT8249719A0 (it) 1982-12-22
SE453088B (sv) 1988-01-11
SG29787G (en) 1987-07-17
NL193283B (nl) 1999-01-04
NL8204970A (nl) 1983-07-18
PT76036A (en) 1983-01-01
KE3709A (en) 1987-04-16
IE823067L (en) 1983-06-28
GB2114122A (en) 1983-08-17
FI824442L (fi) 1983-06-29
DK162389C (da) 1992-03-09
FI70891B (fi) 1986-07-18
SE8207425L (sv) 1983-08-12
DE3248160A1 (de) 1983-07-07
JPH06293753A (ja) 1994-10-21
CH656383A5 (de) 1986-06-30
AU9108382A (en) 1983-07-07
JPH0368875B2 (fr) 1991-10-30
ES524945A0 (es) 1985-08-01
CY1379A (en) 1987-08-07
CA1244426A (fr) 1988-11-08
ZA828549B (en) 1983-09-28
FR2518993A1 (fr) 1983-07-01
US4423049A (en) 1983-12-27
SE8207425D0 (sv) 1982-12-27
DK573182A (da) 1983-06-29
DK162389B (da) 1991-10-21
KR870001045B1 (ko) 1987-05-26
BE895504A (fr) 1983-06-28
IE54619B1 (en) 1989-12-20
GR77045B (fr) 1984-09-04
AU555797B2 (en) 1986-10-09
PT76036B (en) 1985-12-16
JPS58118582A (ja) 1983-07-14
FI70891C (fi) 1986-10-27
GB2114122B (en) 1985-11-27
AT382373B (de) 1987-02-25
LU84561A1 (fr) 1983-09-08
ATA469882A (de) 1986-07-15
ES8405786A1 (es) 1984-06-16
KR840002827A (ko) 1984-07-21
ES8506696A1 (es) 1985-08-01
ES518510A0 (es) 1984-06-16
NL193283C (nl) 1999-05-06
DE3248160C2 (de) 1993-12-09
IT1158039B (it) 1987-02-18

Similar Documents

Publication Publication Date Title
FR2518993B1 (fr) 2-(4-((4,4-dialkyl-2,6-piperidinedion-1-yl))-1-piperazinyl) pyrimidines, leur preparation et leur application pharmacologique
IT8522168A0 (it) Indumento monouso per il contenimento di escreti
DK141992A (da) 2-(3-oxocycloalken-1-yl)-aminobenzonitril-derivater
FR2518994B1 (fr) 2-(4-(4,4-dialkyl-2,6-piperidinedion-1-yl) butyl)-1-pyperazinyl) pyridines et leur application pharmacologique
DE3571618D1 (de) 2-(n-substituteguanidino)-4-hetero-arylthiazole antiulcer agents
IT1211096B (it) Pirimidine e s.triazinici adattivita' ipolipidemizzante.
DE3775802D1 (de) 2-(4'-alkoxyphenyl)-5-alkylpyridine.
FI862769A0 (fi) (r)-2-(4-(5-klor-3-fluorpyridin- 2-yloxi)-fenoxi)-propionsyrapropinylestrar med herbicid verkan.
DK158310C (da) Analogifremgangsmaade til fremstilling af substituerede 2,4-diamino-5-piperazinyl-pyrimidiner samt mellemprodukter til brug herved
DK248685D0 (da) Herbicide 2-(2-imidazolin-2-yl)-fluoralkoxy-, alkenyloxy- og alkynyloxypyridiner og -quinoliner
DK142086D0 (da) 4-(isoxazolyl)-thiazol-2-oxaminsyrederivater
DE3588103D1 (de) 5-Fluorouracil-Derivate
BE889204A (fr) Derives de 4-(3-iodopropargyloxy)-pyrimidine et leur procede de preparation
DK240585D0 (da) 4-(2-(dialkylamino)ethyl)isatiner
ATE93523T1 (de) 4-(2-pyrimidyl)-1-piperazinyl-substituierte heterozyklische carbonylderivate.
NO882861D0 (no) Fremgangsmaate for fremstilling av krystallinsk 2-(1-pentyl-3-guanidino) 4-(2-metyl-4-imidazolyl)-tiazol-dihydroklorid-trihydrat.
AU517046B2 (en) 4-[4-(2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl-methyl)-1-piperazinyl]-6-methyl pyrimidine derivatives
ES509853A0 (es) "procedimiento para la preparacion de derivados de 4-(5)-alcohil-mercaptoimidazoles".
IE870556L (en) 4-(2-pyrimidinyl)-1-piperazinyl heterocyclic carbonyl¹derivatives
FI822268A0 (fi) Foerbaettrat foerfarande att framstaella 2,4-diamino-5-(3',4'5'-trimetoxybenzyl)pyrimidin
IE841878L (en) 2-(pyridylalkylamino) pyrimidines
FI844458L (fi) Framstaellning av kamomillextrakt och eterisk olja ur en tetraploid kamomillvaext.
IE810824L (en) 2-(1-piperazinyl)-4-pyrimidinamines
IT8322708A0 (it) Derivati del5-amino-(3,4'-bipiridin)-6(1h)-one.
IT1230056B (it) Derivato di 4-(piperidin-1-il) piridina ad attivita' antifibroplastica.